rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BEAM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Positive Trial Results Could Be A Big Moment For Beam Therapeutics (BEAM)
      5h agoYahoo FinanceBEAM
      Beam Therapeutics at Jefferies: base editing moves toward market
      14h agoInvesting.comBEAMJEF
      Beam Therapeutics - Market Selling Promising Data Readouts Doesn't Add Up (NASDAQ:BEAM)
      Nov 12Seeking AlphaBEAM
      BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
      Nov 11Yahoo FinanceBEAM
      H.C. Wainwright reiterates Buy on Beam Therapeutics stock on trial data
      Nov 11Investing.comBEAM
      Beam Therapeutics (BEAM) Clears A Key Trial As The Undervalued Case Faces A Test

      Beam Therapeutics (BEAM) just crossed a major clinical hurdle. The firm reported that its sickle cell therapy candidate, ristoglogene autogetemcel, met all primary and secondary endpoints in the BEACON Phase 1/2 trial. Beam Therapeutics has not seen that clinical success translate into short term share price strength, with the stock down 6.9% on a 1 day basis and weaker over the past week, month and quarter. However, the 1 year total shareholder return of 11.9% and 3 year total shareholder...

      Nov 11Yahoo FinanceBEAM
      Beam Therapeutics to seek approval of SCD cell therapy after trial success
      Nov 10Yahoo FinanceBEAM
      Beam Therapeutics at guggenheim healthcare conference: pipeline builds
      Nov 10Investing.comBEAM
      Jones Trading initiates Beam Therapeutics stock coverage with buy rating
      Nov 5Investing.comBEAM
      Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
      Nov 4Yahoo FinanceBEAM
      Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
      Nov 3Yahoo FinanceBEAM
      Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
      Nov 3Yahoo FinanceBEAM
      Beam Therapeutics surges 64% after InvestingPro’s undervalued call By Investing.com
      Oct 31Investing.comBEAM
      Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a - Slideshow (NASDAQ:BEAM) 2026-10-29

      2026-10-29. The following slide deck was published by Beam Therapeutics Inc.

      Oct 29Seeking AlphaBEAM
      Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Beam Therapeutics (BEAM)

      Tipranks Press Release.

      Oct 29The Globe and MailBEAM
      Why Beam Therapeutics Stock Is Up 15.6% And What's Next
      Oct 29Yahoo FinanceBEAM
      Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

      Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

      Oct 29Yahoo FinanceBEAM
      Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Beam Therapeutics (BEAM) and ProKidney (PROK)

      Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.

      Oct 29The Globe and MailBEAMPROK
      Beam Therapeutics (BEAM) Gets a Buy from Citi

      Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailBEAM
      BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside
      Oct 27Yahoo FinanceBEAM
      Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
      Oct 27Yahoo FinanceBEAM
      Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
      Oct 27Yahoo FinanceBEAM
      A New Hope for Gene Editing
      Oct 21BloombergBEAM
      Beam Therapeutics Insider Sold Shares Worth $1,188,745, According to a Recent SEC Filing
      Oct 19Yahoo FinanceBEAM
      Beam Therapeutics CEO John Evans sells $1.19m in company stock
      Oct 17Investing.comBEAM
      Wedbush Remains a Buy on Beam Therapeutics (BEAM)

      Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

      Oct 15The Globe and MailBEAM
      Beam Therapeutics reports early data on gene therapy for GSDIa
      Oct 13Investing.comBEAM
      Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

      BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology co

      Oct 13Yahoo FinanceBEAM
      Wells Fargo Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

      Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailBEAM
      Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative

      In September 2026, Beam Therapeutics filed a lawsuit alleging that former scientist Zi Jun “Emma” Wang stole confidential research to co-found Chinese biotech YolTech Therapeutics and, through it, helped create Serapha Bio using Beam’s trade secrets and patentable know‑how. This dispute underscores intensifying concerns over intellectual property protection and cross‑border competition in gene editing, particularly between U.S. and Chinese biotech companies. We’ll now examine how this...

      Oct 1Yahoo FinanceBEAM
      Beam says Chinese firm, Serapha stole trade secrets (BEAM)
      Sep 30Seeking AlphaBEAMBOLD
      Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM)

      Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028–2029, cash runway/dilution risks, valuation vs peers—read now.

      Sep 29Seeking AlphaBEAM
      Beam sues 2 biotechs, alleging theft of base editing trade secrets
      Sep 29Yahoo FinanceBEAM
      As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
      Sep 28BarchartBEAM
      Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows

      Beam Therapeutics sits in a crowded gene editing field, and its share price history raises a simple question for you as an investor: Is the current US$24.37 price properly reflecting what the business is generating in sales today? Over the past 5 years the stock has fallen 72.1%, which puts the focus squarely on whether the revenue it produces can still justify even the current market value. Recent coverage of the in vivo gene editing market highlights Beam Therapeutics as a key participant...

      Sep 24Yahoo FinanceBEAM
      Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View
      Sep 11Seeking AlphaBEAM
      Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

      Beam Therapeutics Inc. (NASDAQ:BEAM) reported updated Phase 1/2 results on September 8 for BEAM-302, an investigational gene-editing treatment for alpha-1 antitrypsin deficiency, or AATD. Although 38 patients had been treated by August 17, the presented efficacy analysis covered 29 single-dose patients at the June 24 cutoff. Biomarker results extended to 18 months, while overall patient […]

      Sep 10Yahoo FinanceBEAM
      Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow (NASDAQ:BEAM) 2026-09-10
      Sep 10Seeking AlphaBEAM
      Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) Congress - Slideshow
      Sep 10Seeking AlphaBEAM
      Beam Therapeutics at cantor conference: base editing lead comes into focus
      Sep 10Investing.comBEAM
      Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics
      Sep 10Investing.comBEAMGOOG
      Beam Therapeutics at Citi summit: platform gains momentum across pipeline
      Sep 9Investing.comBEAM
      Beam Therapeutics at Wells Fargo conference: base editing gains ground
      Sep 8Investing.comBEAMWFC
      Beam updates Phase 1/2 trial data for gene-editing drug (BEAM)

      Beam Therapeutics (BEAM) stock slips on updated data from a Phase 1/2 trial for BEAM-302, its gene-editing drug for alpha-1 antitrypsin deficiency. Read more here.

      Sep 8Seeking AlphaBEAM
      Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

      Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease. The company shared these findings at the European Respiratory Society Congress 2026, showcasing the genetic medicine’s potential to directly correct the root cause of both liver and

      Sep 8Yahoo FinanceBEAM
      What's Going On With Beam Therapeutics Stock Today? - Beam Therapeutics (NASDAQ:BEAM)
      Sep 8BenzingaBEAM
      Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

      BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corres

      Sep 8Yahoo FinanceBEAM
      Beam Therapeutics names Eric Foster as chief commercial officer
      Sep 1Investing.comBEAM
      Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

      CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. “Eric is an exceptional biopharmaceutical leader w

      Sep 1Yahoo FinanceBEAM
      Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb

      Beam Therapeutics has delivered a sharp 86.5% share price gain over the past year, yet the stock screens as expensive on broader valuation checks, which leaves recent buyers paying up for its gene editing potential without clear support from traditional metrics. The 86.5% 1 year return highlights how strongly sentiment has swung in favor of Beam Therapeutics, even though the business is still early in its commercial journey. Expectations that Beam Therapeutics can eventually turn its gene...

      Aug 26Yahoo FinanceBEAM

      This is the newest page. Registered accounts read further back.